Filing Details

Accession Number:
0001214659-21-003239
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-03-17 17:00:40
Reporting Period:
2021-03-15
Accepted Time:
2021-03-17 17:00:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1737287 Allogene Therapeutics Inc. ALLO Biological Products, (No Disgnostic Substances) (2836) 823562771
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1754937 Alison Moore 210 East Grand Avenue
South San Francisco CA 94080
Chief Technical Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-03-15 6,164 $38.14 102,574 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.96 to $38.395, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  3. Includes 368 shares of the Issuer's common stock acquired by the reporting person on March 15, 2021 pursuant to an employee stock purchase program.